Fiprokil Spot Solution 67 mg for Small Dogs

Main information

  • Trade name:
  • Fiprokil Spot Solution 67 mg for Small Dogs
  • Pharmaceutical form:
  • Spot-on solution
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Fiprokil Spot Solution 67 mg for Small Dogs
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • fipronil
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0468/002
  • Authorization date:
  • 20-03-2013
  • EU code:
  • UK/V/0468/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:September2013

AN:00682/2012

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

BobMartinClear67mgspot-onsolutionforsmalldogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

One0.67mlpipettecontains:

Activesubstance:

Fipronil 67mg

Excipients:

ButyhydroxyanisoleE320 0.134mg

ButylhydroxytolueneE321 0.067mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Spot-onsolution.

Clear,paleambersolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Dogs.

4.2 Indicationsforuse,specifyingthetargetspecies

Treatmentofflea(Ctenocephalidesspp.)andtick(Rhipicephalussanguineusand

Ixodesricinus)infestations.

Fleaswillbekilledwithin24h.Insecticidalefficacyagainstnewinfestationswithadult

fleaspersistsfor8weeks.

Theproducthasapersistentacaricidalefficacyfor4weeksagainstticks

(Rhipicephalussanguineus,Ixodesricinus,Dermacentorreticulatus).

Tickswillusuallybekilledwithin48haftercontactwithFipronil.However,ifticksof

somespecies(Dermacentorreticulatus)arealreadypresentwhentheproductis

applied,alloftheticksmaynotbekilledwithinthefirst48hours.

Revised:September2013

AN:00682/2012

4.3 Contraindications

Donotuseonpuppieslessthan2monthsoldand/orweighinglessthan2kg.Donot

useonsick(e.g.systemicdiseases,fever…)orconvalescentanimals.

Donotuseinrabbits,asadversereactionsandevendeathcouldoccur.

Thisproductisspecificallydevelopedfordogs.Donotuseincats,asthiscouldlead

tooverdosing.

Donotuseonanimalswithknownhypersensitivitytotheactivesubstanceortoany

oftheexcipients.

4.4Specialwarnings<foreachtargetspecies>

Avoidfrequentswimmingorshampooingtheanimalbecausethemaintenanceof

effectivenessoftheproductinthesecaseshasnotbeentested.

Theproductdoesnotpreventticksfromattachingtotheanimals.Iftheanimalhas

beentreatedpriortoexposuretotheticks,thetickswillbekilledinthefirst24-48

hoursafterattachment.Thiswillusuallybepriortoengorgement,minimisingbutnot

excludingtheriskoftransmissionofdiseases.Oncedead,tickswilloftendropoff

theanimal,butanyremainingticksmayberemovedwithagentletwist.

Fleasfrompetsofteninfesttheanimal'sbasket,beddingandregularrestingareas

suchascarpetsandsoftfurnishingswhichshouldbetreated,incaseofmassive

infestationandatthebeginningofthecontrolmeasures,withasuitableinsecticide

andvacuumedregularly.

Foroptimalcontroloffleainfestationinmulti-pethousehold,alldogsandcatsinthe

householdshouldbetreatedwithasuitableinsecticide.

4.5 Specialprecautionsforuse

i) Specialprecautionsforuseinanimals

Animalsshouldbeweighedaccuratelypriortotreatment.

Avoidc ontactwiththeanimal’seyes.Inthecaseofaccidentaleyecontact,

immediatelyandthoroughlyflushtheeyeswithwater.

Itisimportanttomakesurethattheproductisappliedtoanareawheretheanimal

cannotlickitoff,andtomakesurethatanimalsdonotlickeachotherfollowing

treatment.

Donotapplytheproductonwoundsordamagedskin.

ii) Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Thisproductcancausemucousmembraneandeyeirritation.Therefore,contact

betweentheproductandthemouthoreyesshouldbeavoided.

Revised:September2013

AN:00682/2012

Inthecaseofaccidentaleyecontact,immediatelyandthoroughlyflushtheeyeswith

water.Ifeyeirritationpersistsseekmedicaladviceandshowthepackageleafletor

thelabeltothephysician.

Donotsmoke,drinkoreatduringapplication.

Avoidcontentscomingintocontactwiththefingers.Ifthisoccurs,washhandswith

soapandwater.Washhandsafteruse.

Animalsorpeoplewithaknownhypersensitivitytofiproniloranyoftheother

ingredientsshouldavoidcontactwiththeproduct.

Treatedanimalsshouldnotbehandleduntiltheapplicationsiteisdry,andchildren

shouldnotbeallowedtoplaywithtreatedanimalsuntiltheapplicationsiteisdry.Itis

thereforerecommendedthatanimalsarenottreatedduringtheday,butshouldbe

treatedduringtheearlyevening,andthatrecentlytreatedanimalsshouldnotbe

allowedtosleepwithowners,especiallychildren.

iii) Environmentalwarning

Fipronilmayadverselyaffectaquaticorganisms.Dogsshouldnotbeallowedtoswim

inwatercoursesfor2daysafterapplication.

iv) Otherprecautions

Theproductmayhaveadverseeffectsonpainted,varnishedorotherhousehold

surfacesorfurnishings.

4.6Adversereactions(frequencyandseriousness)

Iflickingoccurs,abriefperiodofhypersalivationmaybeobservedduemainlytothe

natureofthecarrier.

Amongtheextremelyraresuspectedadversereactions,transientcutaneous

reactionsontheapplicationsite(skindiscoloration,localalopecia,pruritus,

erythema)andgeneralpruritusoralopeciahavebeenreportedafteruse.

Exceptionally,hypersalivation,reversibleneurologicsymptoms(hyperesthesia,

depression,nervoussymptoms),vomitingorrespiratorysymptomshavebeen

observedafteruse.

4.7Useduringpregnancyandlactation

Laboratorystudiesusingfipronilhavenotshownanyevidenceofteratogenicor

embryotoxiceffect.Studieshavenotbeencarriedoutwiththisproductinpregnant

andlactatingbitches.Useinpregnancyandlactationonlyinaccordancewith

professionalveterinaryadviceandabenefit/riskassessment.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9 Amountstobeadministeredandadministrationroute

Routeofadministrationanddosage:

Revised:September2013

AN:00682/2012

Externaluseonly.Administerbytopicalapplicationtotheskinaccordingtothe

bodyweightasfollows:1pipetteof0.67mlperdogweighingover2kgandupto10

kgbodyweight.

Methodofadministration:

Removethepipettefromtheblisterpackaging.Holdthepipetteinanuprightposition

andsnapoffthetopsectionofthecap,therebyopeningthepipette.

Partyourdog’scoatuntiltheskinisvisible.Placethetipofthepipettedirectly

againstthebaredskinandsqueezegently.Emptyapproximatelyhalfthecontentsat

eachoftwopointsalongthedog’sback,preferablyatthebaseoftheheadand

betweentheshoulderblades.Squeezethepipetteseveraltimestoensuredosingis

complete.Avoidapplyingthesolutionontothefuranddonotrubintotheskin.

Applicationofthesolutionasdirectedminimisesthepossibilitythattheanimalwilllick

thesolutionoff.Donotallowpetstolickeachotheraftertreatment.

Careshouldbetakentoavoidexcessivewettingofthehairwiththeproductsince

thiswillcauseastickyappearanceofhairsatthetreatmentspot.However,should

thisoccur,itwillusuallydisappearwithin24-48hourspostapplication.Crystalsmay

beseenonthehairandslightscalingmayoccurwithin24-48hoursafterapplication.

Treatmentschedule:

Foroptimalcontroloffleaand/ortickinfestationthetreatmentschedulecanbebased

onthelocalepidemiologicalsituation.

Theminimumintervalbetweentwotreatmentsis4weeks.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noadverseeffectswereobservedintargetanimalsafetystudiesin2month-old

puppies,growingdogsanddogsweighingabout2kgtreatedwith5timesthe

therapeuticdoseonceamonthfor3consecutivemonths.Theriskofadverseeffects

(seesection4.6)mayincreaseincasesofoverdose.

4.11Withdrawalperiod(s)

Notapplicable.

Revised:September2013

AN:00682/2012

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Ectoparasiticidesfortopicaluse.

ATCvetcode:QP53AX15

5.1 Pharmacodynamicproperties

Fipronilisaninsecticideandacaricidebelongingtothephenylpyrazolefamily.Itacts

byinhibitingtheGABAcomplex,bindingtothechloridechannelandtherebyblocking

pre-andpost-synaptictransferofchlorideionsacrosscellmembranes.Thisresults

inuncontrolledactivityofthecentralnervoussystemanddeathofinsectsoracarids.

Fipronilexhibitsaninsecticidalandacaricidalactivityagainstfleas(Ctenocephalides

spp),ticks(Rhipicephalusspp,IxodessppincludingIxodesricinus)inthedog.

5.2Pharmacokineticparticulars

Fipronilismainlymetabolisedtoitssulfonederivative(RM1602),whichalso

possessesinsecticidalandacaricidalproperties.Theconcentrationsoffipronilonthe

hairdecreasewithtime.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

ButylhydroxyanisoleE320

ButylhydroxytolueneE321

Benzylalcohol

Diethyleneglycolmonoethylether

6.2Incompatibilities

Noneknown.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:2years.

6.4.Specialprecautionsforstorage

Storebelow25

C,inadryplaceintheoriginalpackaging.

6.5Natureandcompositionofimmediatepackaging

Whiteopaqueorblueoryellowtranslucentpolypropylenesingle-dosepipettes

containinganextractablevolumeof0.67mlpackagedinaclearPVCblisterclosedby

heatsealingwithaluminiumfoilandplacedinacartonboxorblistercard.

Blistercardsorboxesof1,2,3,4,5or6pipettes.

Notallpacksizesmaybemarketed.

Revised:September2013

AN:00682/2012

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.Fipronilmayadverselyaffectaquaticorganisms.Donotcontaminate

ponds,waterwaysorditcheswiththeproductoremptycontainer.

7. MARKETINGAUTHORISATIONHOLDER

BobMartinUKLtd.

WemberhamLane

Yatton

Somerset

BS494BS

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm00715/4120

9. DATEOFFIRSTAUTHORISATION

12December2011

10.DATEOFREVISIONOFTHETEXT

September2013

APPROVED 20/09/13

27-11-2018

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

INNUENDO: A cross‐sectoral platform for the integration of genomics in the surveillance of food‐borne pathogens

Published on: Mon, 26 Nov 2018 Abstract In response to the EFSA call New approaches in identifying and characterizing microbial and chemical hazards, the project INNUENDO (https://sites.google.com/site/theinnuendoproject/) aimed to design an analytical platform and standard procedures for the use of whole‐genome sequencing in surveillance and outbreak investigation of food‐borne pathogens. The project firstly attempted to identify existing flaws and needs, and then to provide applicable cross‐sectorial ...

Europe - EFSA - European Food Safety Authority Publications

22-10-2018

Promise Pharmacy Issues Voluntary Nationwide Recall of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% Sterile Due to Small Particulate Floating in the Solution

Promise Pharmacy Issues Voluntary Nationwide Recall of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% Sterile Due to Small Particulate Floating in the Solution

Promise Pharmacy is voluntarily recalling one lot of Prednisolone and Gatifloxacin Ophthalmic Solution 1%/0.5% sterile, 3ml vials, to the patient consumer level. The product has been found to have unidentified small particulate floating in the solution.

FDA - U.S. Food and Drug Administration

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

There are no news related to this product.